Lundbeck

Turku, 18-12-2012 — /europawire.eu/ — Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) (nalmefene; an … Read the full press release →

18-12-2012 — /europawire.eu/ — Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson’s disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of … Read the full press release →

Selincro offers treatment in conjunction with psychosocial support 14-12-2012 — /europawire.eu/ — The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Selincro, a medicinal product intended for the reduction … Read the full press release →